title: Morphea associated with the use of adalimumab: a case report and review of the literature.
abstract: Therapy with TNF blockers may induce cutaneous adverse events, but the development of morphea, a localized scleroderma lesion, is extremely infrequent. We describe a 37-year-old man with ankylosing spondylitis treated with adalimumab who developed morphea lesions in the lower limbs after 12 months of treatment. Adalimumab was discontinued, which resulted in progressive improvement in the skin lesions, with only mild hyperpigmentation remaining. We also review reports of morphea and other adverse cutaneous events related to anti-TNF treatment.
authors.affiliation: Arthritis Unit, Department of Rheumatology, Hospital Clinic, University of Barcelona, Villarroel 170, Stairway 11, 2nd Floor, 08036, Barcelona, Spain. julramga@hotmail.com
authors.forename: Julio
authors.initials: J
authors.lastname: Ramírez
authors.forename: M Victoria
authors.initials: MV
authors.lastname: Hernández
authors.forename: Javier
authors.initials: J
authors.lastname: Galve
authors.forename: Juan D
authors.initials: JD
authors.lastname: Cañete
authors.forename: Raimon
authors.initials: R
authors.lastname: Sanmartí
mesh_terms: D000068879:Adalimumab; D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects*; D006801:Humans; D035002:Lower Extremity; D008297:Male; D012594:Scleroderma, Localized / Q000139:chemically induced* / Q000175:diagnosis; D012867:Skin / Q000187:drug effects / Q000473:pathology; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D028761:Withholding Treatment
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab